The @Sarepta saga brought to light the veritable communications disaster that has confused the #Duchennemusculardystrophy community and exposed leaks within the #FDA. And it didn’t just start with Sarepta and #Elevidys.
My latest for @BioSpace
https://t.co/VVj9Ki5TxL
@RWPUSA Thanks for sharing Richard! As a journalist and a true believer in the power of science to change the world, I am very alarmed by the current situation.
As I told Heather McKenzie here: “There’s objective truth in science, and the extreme left and extreme right have always wanted to deny objective truth....most of the politicization of science has been on the far right in the United States.”
https://t.co/g8jZSQV9Rp
🧠 HUGE NEWS - $AZN out of Neuro!!!!
Big loss for patients….disappointing
“CNS really is probably better managed by other companies that have a focus on that.”
“We have closed our neuro programs and identified partners for some of them,” noted Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca.
https://t.co/8HOci9qLLK
#biopharma conference season is in full swing, and our very own @JefAkst and @Slabodkin will be at hashtag#ASGCT24 in Baltimore next week. https://t.co/WgYSWHxOtb
Join @Slabodkin, Tyler Patchen and I as we discuss @sanofi#layoffs, #GLP1s, a new boxed warning on CAR-T therapies, and as an added bonus, the proper way to pronounce "Sanofi". @JefAkst
https://t.co/DWkFrxwErg
Early data indicate stem cell therapies could help people with Parkinson's disease generate dopamine again. Wouldn't that be something? #Parkinsons@biospace
https://t.co/mzVf3MQ6qF
Metabolic dysfunction-associated steatohepatitis experts welcomed #Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results. Writes @biospace's @hmac8.
#pharma#biospace
https://t.co/xLKjt3IBgn
Just when it seems like #geneediting can't get any hotter—what about editing parts of the genetic code beyond the DNA itself? @EpicBiotech #Innovation@biospace https://t.co/dhzCktb3xc
The recent @US_FDA decision will likely mean more #Medicare patients gain access to the blockbuster weight loss drug, experts say. Meanwhile, results continue to roll in for GLP-1 agonists for conditions beyond diabetes and obesity.
#glp1#pharma#biospace
https://t.co/BOvfY33lM4
A very deserving group of patients got a much-needed new treatment option yesterday as the #FDA approved the third #Duchenne muscular dystrophy treatment in nine months. @biospace@ITALFARMACO
https://t.co/XZo3wyRkie
A very deserving group of patients got a much-needed new treatment option yesterday as the #FDA approved the third #Duchenne muscular dystrophy treatment in nine months. @biospace@CureDuchenne@ITALFARMACO
Nice insights from Chantal Dresner and the BioSpace marketing team! Nice to see an "incremental improvement" in the #gendergap, but faster progress is sorely needed. https://t.co/yfkunJNWDR
In one of this year's most anticipated #FDA decisions, the agency approved the first-ever therapy for metabolic dysfunction-associated steatohepatitis. Congratulations to @Madrigal Pharmaceuticals! @BioSpace@FDA#fdaapproval https://t.co/LBSCzv8XD1
Centers for Disease Control and Prevention: Push CDC to consider Long COVID a chronic illness - Sign the Petition! https://t.co/TmCw8qlpOy via @CdnChange